ong term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritis

Phase 4

Recruiting

• Conditions: Inflammatory rheumatic disease; 10023213

• Registration Number: NL-OMON39013
• Lead Sponsor: Jan van Breemen Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Patients * 18 years old at treatment initiation
Patients informed and accepting to participate (Written informed consent)
Patients diagnosed with established moderate to severe active RA as per the 1987 ACR criteria/2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria
Patients who at their physician*s discretion are initiated with abatacept SC.

Exclusion Criteria

Patients currently participating in any interventional clinical trial in RA
Contraindications against abatacept SC treatment.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Efficacy will be determined in comparison to baseline by measuring disease<br /><br>activity, radiological progression and<br /><br>functional capacity during follow-up. Safety will be determined by the<br /><br>occurrence of side effects. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>nvt</p><br>